Clinical Trials

Telehealth Ketamine for Depression: Review Insights

Evaluating telehealth-supported ketamine for depression and anxiety; implications for future clinical practices and policies.

Published June 11, 2026 Read 1 min 288 words By The Psychedelic Journal

Telehealth and Ketamine: A New Frontier

The recent systematic review published on June 11, 2026, in PubMed evaluates the use of telehealth-supported ketamine treatment for depression and anxiety. As mental health care increasingly integrates telehealth, understanding its role in psychedelic treatment becomes imperative. This review highlights the potential of telehealth-supported ketamine to improve access to mental health care.

Mechanism and Context

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has shown promise in rapidly alleviating symptoms of depression and anxiety. Traditionally administered in clinical settings, the advent of telehealth presents a novel delivery method. This review assessed multiple studies that utilized telehealth platforms to support ketamine administration, focusing on patient outcomes, safety, and feasibility.

Policy and Research Implications

The findings from this review could significantly influence future clinical practices and policy decisions. By demonstrating that telehealth can effectively support ketamine treatment, the review suggests a model for expanding access to psychedelic-assisted therapies. Policymakers may consider these findings when drafting regulations that govern telehealth and psychedelic treatments, potentially leading to broader adoption and integration into standard care practices.

Risks and Unknowns

Despite the positive sentiment, several risks and unknowns remain. The review underscores the need for standardized protocols to ensure patient safety and treatment efficacy. Additionally, the long-term effects of telehealth-supported ketamine treatment are not yet fully understood, necessitating further research. Concerns about data security and patient privacy in telehealth settings also require attention.

Looking Forward

As telehealth continues to evolve, its role in psychedelic-assisted therapies like ketamine treatment will likely expand. Future research should focus on optimizing telehealth protocols and addressing the current gaps in knowledge. By doing so, the mental health field can better harness the potential of telehealth to deliver safe and effective treatments to a broader population.

Primary source: https://pubmed.ncbi.nlm.nih.gov/42277616/ — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.